| Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia 2010 · G1 · Men with benign prostatic hyperplasia who were candidates for transurethral resection of the prostate or open prostatectomy; age not reported | 320 mg | 60 days | 72 |
| A detailed safety assessment of a saw palmetto extract 2008 · saw palmetto extract · Men aged 50 years or older with at least moderately severe lower urinary tract symptoms and benign prostatic hyperplasia | 320 mg | 1 year | — |
| The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study 2019 · Group B · Men with NIH type II chronic bacterial prostatitis and recurrent enterobacteriaceae infections | 320 mg | 24 weeks | — |
| Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®) 2014 · Group B (antibiotic and supplement) · Adult men aged 19–54 with chronic bacterial prostatitis | 320 mg | 30 days | 77 |
| The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study 2019 · Group A · Men with NIH type II chronic bacterial prostatitis and recurrent enterobacteriaceae infections | 320 mg | 24 weeks | — |
| Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study 2002 · Permixon · Men with symptomatic benign prostatic hyperplasia (I-PSS ≥10); age not reported | 320 mg | 1 year | 350 |
| [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study] 2002 · Permixon · Men with symptomatic benign prostatic hyperplasia and I-PSS ≥10 | 320 mg | 1 year | 350 |
| Safety and toxicity of saw palmetto in the CAMUS trial 2013 · Saw palmetto (SP) arm · Men aged 45 years or older with lower urinary tract symptoms (AUASI score 8–24) | 320 mg | 72 weeks | 176 |
| The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial 2021 · Serenoa repens group · Men aged 18–50 with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) | 320 mg | 12 weeks | 152 |
| Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? 2013 · SR group · Men with lower urinary tract symptoms due to benign prostatic hyperplasia | 320 mg | 26 weeks | 97 |
| Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? 2013 · TAM + SR group · Men with lower urinary tract symptoms due to benign prostatic hyperplasia | 320 mg | 26 weeks | 81 |
| Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis 2004 · Permixon group · Adults with severe lower urinary tract symptoms (IPSS >19) and benign prostatic hyperplasia | 320 mg | 1 year | 65 |
| [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis] 2004 · Permixon group · Adults with severe lower urinary tract symptoms (IPSS >19) and benign prostatic hyperplasia | 320 mg | 1 year | 65 |
| Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study 2015 · TAM+SR group · men with symptomatic benign prostatic hyperplasia (IPSS ≥10) | 320 mg | 1 year | 60 |
| [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue] 2019 · Group II · Patients with benign prostatic hyperplasia associated with chronic inflammation; age and sex not further specified | 320 mg | 90 days | 51 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 3 (Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 320 mg | 90 days | 50 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 5 (tadalafil/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 320 mg | 90 days | 50 |
| An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study 2013 · Serenoa repens · Men aged 45–71 with LUTS due to BPH and erectile dysfunction | 320 mg | 90 days | 46 |
| Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study 2022 · SPE treatment (active) group · Women older than 50 years with frequent urination, nocturia, and/or urgency for at least 2 months; urinary symptoms did not require medical treatment | 320 mg | 12 weeks | 38 |
| Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments 2019 · Serenoa repens group · Men aged 18–70 with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) | 320 mg | 6 weeks | 34 |
| Beneficial effects of saw palmetto (Serenoa repens) fruit extract on the urinary symptoms of healthy Japanese adults with possible lower urinary tract symptoms: A randomized, double-blind, placebo-controlled study 2025 · SPE group · Healthy Japanese men and women aged 50 years or older with concerns about frequent urination | 320 mg | 12 weeks | 33 |
| [Efficacy and safety of № I Empirical Prescription for Chronic Prostatitis in the treatment of type Ⅲ refractory chronic prostatitis] 2018 · control group · Adults with type III refractory chronic prostatitis and damp-heat/blood-stasis syndrome; age and sex not reported | 320 mg | 8 weeks | 23 |
| BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay 2003 · Permixon group · Men with BPH; mean age 65.7 years | 320 mg | 90 days | 12 |
| Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens 1999 · one 160-mg capsule twice daily [BID] · Outpatients with symptomatic benign prostatic hyperplasia; age and sex not stated | 320 mg | 90 days | — |
| The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study 2019 · HESr · Patients with histologically confirmed prostatic inflammation; age and sex not specified | 320 mg | 26 weeks | — |
| Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study 2026 · Alfuzosin plus HESr · Treatment-naïve men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia, IPSS > 7 and prostate volume > 30 cc | 320 mg | 1 year | — |
| [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue] 2019 · Group I · Patients with benign prostatic hyperplasia associated with chronic inflammation; age and sex not further specified | 320 mg | 90 days | 51 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 6 (L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 320 mg | 90 days | 50 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 7 (tadalafil/L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 320 mg | 90 days | 50 |
| The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results 2025 · active treatment · Healthy men and women aged 25–65 with self-perceived thinning hair | 160 mg | 90 days | 40 |
| The Safety and Efficacy of a Novel Saw Palmetto (Serenoa repens) Extract for Promoting Hair Growth in Adults With Self-Perceived Thinning Hair: 180-Day Results 2026 · active treatment · Healthy men and women aged 25–65 with self-perceived hair thinning | 160 mg | 180 days | 40 |
| Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens 1999 · two 160-mg capsules once daily (OD) · Outpatients with symptomatic benign prostatic hyperplasia; age and sex not stated | 160 mg | 90 days | — |
| The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens 2002 · Two 80-mg tablets twice daily · Adult men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia | 160 mg | 26 weeks | — |
| The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens 2002 · Two 80-mg tablets three times daily · Adult men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia | 240 mg | 26 weeks | — |
| Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin 2006 · PRO 160/120 (Prostagutt forte) group · Elderly out-patients with lower urinary tract symptoms caused by benign prostatic hyperplasia and initial I-PSS score of at least 13 | 320 mg | 60 weeks | — |
| Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial 2005 · PRO 160/120 · Elderly men with lower urinary tract symptoms caused by benign prostatic hyperplasia | 320 mg | 48 weeks | 129 |
| Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial 2005 · PRO 160/120 after placebo · Elderly men with lower urinary tract symptoms caused by benign prostatic hyperplasia, initially assigned to placebo | 320 mg | 24 weeks | 128 |
| Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial 2007 · PRO 160/120 group and all patients during the open-label follow-up · Elderly men with moderate or severe lower urinary tract symptoms caused by benign prostatic hyperplasia | 320 mg | 96 weeks | — |
| Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects 2025 · Group A (drug treatment and dietary supplementation) · Adults with mild-to-severe androgenic alopecia or female androgenic alopecia; men aged over 18 years and women of age appropriate for treatment | 320 mg | 26 weeks | 106 |
| Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia 2015 · HESr · Men aged 45–85 with benign prostatic hyperplasia-related lower urinary tract symptoms | 320 mg | 90 days | 102 |
| Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients 1992 · Serenoa repens extract group · Patients with benign prostatic hypertrophy who had not previously been treated; age and sex not stated | 480 mg | 90 days | 18 |
| [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon] 2004 · Permixon, 3 months · Patients with benign prostatic hyperplasia; age and sex details not reported | 320 mg | 90 days | 12 |
| [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon] 2004 · Permixon, 6 months · Patients with benign prostatic hyperplasia; age and sex details not reported | 320 mg | 26 weeks | 12 |
| [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon] 2004 · Permixon, 12 months · Patients with benign prostatic hyperplasia; age and sex details not reported | 320 mg | 1 year | 12 |
| Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia 2005 · SR-treated group · Men with symptomatic benign prostatic hyperplasia | 320 mg | 90 days | 12 |
| [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate] 2004 · experimental group · Patients with benign prostatic hyperplasia undergoing transurethral resection of the prostate; age and sex details not reported | 320 mg | 8 weeks | — |
| Endocrine and lipid responses to chronic androstenediol-herbal supplementation in 30 to 58 year old men 2001 · AND-HB · Healthy men aged 30–58 years | 480 mg | 4 weeks | 28 |
| Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men 2001 · DION · Healthy men aged 30–59 years | 540 mg | 4 weeks | 28 |